Nanosys | GenomeWeb

Nanosys

Nanomal, a European Union-funded public-private consortium developing a handheld device for rapid, point-of-care molecular diagnosis of malaria and drug resistance, said this week that the instrument is a year ahead of schedule and will be ready for field testing later this year.

QuantumDx is heading a UK-based public-private partnership to develop a chip-based molecular profiling tool for diagnosing and staging cancer, and potentially guiding oncology treatments.

Tech Transfer Tidbits

Premium

Pfizer and UCL to develop stem-cell therapies for AMD; Clarient licenses breast cancer biomarkers from Indiana U; Nanosys and Harvard to outlicense nanowire IP; Luminex settles with SUNY and U of Illinois, and more …

Short Reads

Premium

Life Technologies, J. Craig Venter Institute, BioNanomatrix, Nanosys, Geospiza, HDF Group, Pressure BioSciences, Cofactor Genomics, Ambry Genetics, Affymetrix, Navigenics, Enzymatics, New York State Department of Health, University of Washington

Life Technologies is looking to expand uses of its quantum dot technology beyond life sciences and into applied fields, such as counterfeit detection.

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.